AI professor who survived cancer turns talents to war on COVID

As an academic AI expert, Pascale Fung, PhD, dove into the scientific research when she was diagnosed with breast cancer in 2015. The time investment rewarded her with a depth of understanding that has helped shape her life as a cancer survivor.

This week she extrapolates some takeaways for researchers and clinicians battling COVID-19.

Writing for a lay audience via the World Economic Forum, Fung, a professor of electronic and computer engineering at Hong Kong University, highlights ways researchers can leverage AI to parry the pandemic.

“Machine learning is already being used to predict the speed and pattern of COVID-19 spread, and to enable the research for a vaccine, but it has rarely been used to process medical research papers in a large scale before,” she writes. “It could prove game-changing when it comes to COVID-19 research.”

Fung describes her own team’s work with natural language processing. They’ve built a system that can answer questions on COVID with continually updated information sourced to the fast-growing library of scientific publications.

And they’re offering the system’s source code to anyone who wants it, hoping other developers will use it to advance the science on COVID.

“The fight against COVID-19 has brought untold misery and destruction to the world, but it has also shown what we can achieve if we work together,” Fung writes. “The open and collaborative nature of AI research and development across borders show us what such joint progress might look like in the future.”

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.